Venrock Healthcare Capital Partners III, L.P. 13D and 13G filings for Enliven Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-05-15 4:35 pm Sale | 2026-03-31 | 13G | ENLIVEN THERAPEUTICS INC ELVN | Venrock Healthcare Capital Partners III, L.P. | 1,726,331 2.800% | -1,500,000 (-46.49%) | Filing |
| 2025-11-14 5:32 pm Sale | 2025-09-30 | 13G | ENLIVEN THERAPEUTICS INC ELVN | Venrock Healthcare Capital Partners III, L.P. | 3,226,331 5.400% | -800,000 (-19.87%) | Filing |
| 2024-11-14 5:48 pm Purchase | 2024-09-30 | 13G | ENLIVEN THERAPEUTICS INC ELVN | Venrock Healthcare Capital Partners III, L.P. | 4,026,331 8.500% | 1,071,429 (+36.26%) | Filing |
| 2024-02-14 8:53 pm Purchase | 2023-12-31 | 13G | ENLIVEN THERAPEUTICS INC ELVN | Venrock Healthcare Capital Partners III, L.P. | 2,954,902 7.200% | 740,760 (+33.46%) | Filing |
| 2023-03-13 4:01 pm Purchase | 2023-03-03 | 13G | ENLIVEN THERAPEUTICS INC ELVN | Venrock Healthcare Capital Partners III, L.P. | 2,214,142 5.400% | 2,214,142 (New Position) | Filing |